The Cerament G implantable device/drug combination provides a pathway for a single-stage approach to bone infections for those susceptible to bone fractures and foot ulcers.
Surgeons and hospitals can receive up to 65 percent reimbursement when using Cerament G, according to the email. Reimbursement is only applicable to Medicare patients.
Treatment cost savings are due to the product’s effectiveness, which reduces the need for follow-up procedures and post-surgical complications.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
